» Articles » PMID: 34028750

Animal and Human Models of Tissue Repair and Fibrosis: An Introduction

Overview
Specialty Molecular Biology
Date 2021 May 24
PMID 34028750
Citations 9
Authors
Affiliations
Soon will be listed here.
Abstract

Reductionist cell culture systems are not only convenient but essential to understand molecular mechanisms of myofibroblast activation and action in carefully controlled conditions. However, tissue myofibroblasts do not act in isolation and the complexity of tissue repair and fibrosis in humans cannot be captured even by the most elaborate culture models. Over the past five decades, numerous animal models have been developed to study different aspects of myofibroblast biology and interactions with other cells and extracellular matrix. The underlying principles can be broadly classified into: (1) organ injury by trauma such as prototypical full thickness skin wounds or burns; (2) mechanical challenges, such as pressure overload of the heart by ligature of the aorta or the pulmonary vein; (3) toxic injury, such as administration of bleomycin to lungs and carbon tetrachloride to the liver; (4) organ infection with viruses, bacteria, and parasites, such as nematode infections of liver; (5) cytokine and inflammatory models, including local delivery or viral overexpression of active transforming growth factor beta; (6) "lifestyle" and metabolic models such as high-fat diet; and (7) various genetic models. We will briefly summarize the most widely used mouse models used to study myofibroblasts in tissue repair and fibrosis as well as genetic tools for manipulating myofibroblast repair functions in vivo.

Citing Articles

Physical Exercise: A Promising Treatment Against Organ Fibrosis.

Ma X, Liu B, Jiang Z, Rao Z, Zheng L Int J Mol Sci. 2025; 26(1.

PMID: 39796197 PMC: 11720236. DOI: 10.3390/ijms26010343.


Blockade of Sialylation with Decrease in Polysialic Acid Levels Counteracts Transforming Growth Factor β1-Induced Skin Fibroblast-to-Myofibroblast Transition.

Fioretto B, Rosa I, Tani A, Andreucci E, Romano E, Sgambati E Cells. 2024; 13(12.

PMID: 38920695 PMC: 11201575. DOI: 10.3390/cells13121067.


Sanglifehrin A mitigates multiorgan fibrosis by targeting the collagen chaperone cyclophilin B.

Flaxman H, Chrysovergi M, Han H, Kabir F, Lister R, Chang C JCI Insight. 2024; 9(15).

PMID: 38900587 PMC: 11383833. DOI: 10.1172/jci.insight.171162.


Fibroblast and myofibroblast activation in normal tissue repair and fibrosis.

Younesi F, Miller A, Barker T, Rossi F, Hinz B Nat Rev Mol Cell Biol. 2024; 25(8):617-638.

PMID: 38589640 DOI: 10.1038/s41580-024-00716-0.


Getting the Timing Right: Controlling BCL-2 Inhibition as an Antifibrotic Therapy.

Cooley J, Redente E Am J Respir Cell Mol Biol. 2024; 70(4):231-232.

PMID: 38259233 PMC: 11478124. DOI: 10.1165/rcmb.2023-0436ED.


References
1.
Lazebnik Y . Can a biologist fix a radio?--Or, what I learned while studying apoptosis. Cancer Cell. 2002; 2(3):179-82. DOI: 10.1016/s1535-6108(02)00133-2. View

2.
MacQueen L, Sun Y, Simmons C . Mesenchymal stem cell mechanobiology and emerging experimental platforms. J R Soc Interface. 2013; 10(84):20130179. PMC: 3673151. DOI: 10.1098/rsif.2013.0179. View

3.
Asmani M, Velumani S, Li Y, Wawrzyniak N, Hsia I, Chen Z . Fibrotic microtissue array to predict anti-fibrosis drug efficacy. Nat Commun. 2018; 9(1):2066. PMC: 5970268. DOI: 10.1038/s41467-018-04336-z. View

4.
Mazza G, Al-Akkad W, Rombouts K . Engineering in vitro models of hepatofibrogenesis. Adv Drug Deliv Rev. 2017; 121:147-157. DOI: 10.1016/j.addr.2017.05.018. View

5.
Benny P, Raghunath M . Making microenvironments: A look into incorporating macromolecular crowding into in vitro experiments, to generate biomimetic microenvironments which are capable of directing cell function for tissue engineering applications. J Tissue Eng. 2017; 8:2041731417730467. PMC: 5638150. DOI: 10.1177/2041731417730467. View